Home › Employers › Garuda Therapeutics, Inc.
Garuda Therapeutics, Inc.: H-1B salaries and sponsorship
Garuda Therapeutics, Inc. filed 14 labor condition applications for H-1B and related visas in fiscal years 2023–2026; certified: 14. Median offered salary: $133,306.
Does Garuda Therapeutics, Inc. sponsor H-1B visas?
Garuda Therapeutics, Inc. filed 14 labor condition applications in fiscal years 2023–2026, the latest submitted on Apr 26, 2025. An LCA is the first step of an H-1B petition, so the employer has sponsored or prepared to sponsor H-1B workers; it does not guarantee sponsorship for any particular job. Check the employer's own job listings.
Salaries by job title
| Job title | LCAs | Median salary |
|---|---|---|
| Computational Biologist - Senior Scientist I | 4 | $133,306 |
| Process Development Research Associate | 2 | $83,306 |
| Scientist II, In Vivo Research and Development | 1 | $125,000 |
| Medical Director | 1 | $220,000 |
| Vice President of Research and Development | 1 | $285,848 |
| Chief Therapeutics Officer | 1 | $385,700 |
| Associate Scientist | 1 | $105,000 |
| Executive Director of Technical Operations | 1 | $260,000 |
| VP, Head of Corporate Affairs and Business Development | 1 | $300,000 |
| Senior Stem Cell Scientist | 1 | $124,000 |
Applications by fiscal year
| Fiscal year | LCAs | Median salary |
|---|---|---|
| FY2023 | 1 | $125,000 |
| FY2024 | 2 | $335,774 |
| FY2025 | 8 | $125,306 |
| FY2026 | 3 | $140,000 |
Prevailing wage levels
The Department of Labor sets four prevailing wage levels for each occupation and area, from Level I (entry) to Level IV (fully competent). The employer picks the level that matches the job's requirements.
Where the jobs are
Occupations
- Molecular and Cellular Biologists5
- Biochemists and Biophysicists4
- Natural Sciences Managers2
- Public Relations Managers1
- Industrial Production Managers1
- Marketing Managers1
Latest applications
| Job title | Base salary | Location | Submitted | Start date | Status |
|---|---|---|---|---|---|
| Process Development Research Associate | $90,000 Level I | Cambridge, MA | Apr 26, 2025 | Oct 1, 2025 | Certified |
| Computational Biologist - Senior Scientist I | $140,000 Level II | Cambridge, MA | Apr 25, 2025 | Oct 1, 2025 | Certified, then withdrawn |
| Computational Biologist - Senior Scientist I | $140,000 Level I | Cambridge, MA | Feb 26, 2025 | Feb 28, 2025 | Certified, then withdrawn |
| VP, Head of Corporate Affairs and Business Development | $300,000 Level IV | Walnut Creek, CA | Feb 13, 2025 | Mar 3, 2025 | Certified |
| Computational Biologist - Senior Scientist I | $126,613 Level I | Cambridge, MA | Feb 11, 2025 | Feb 17, 2025 | Certified |
| Process Development Research Associate | $76,613 Level I | Watertown, MA | Feb 4, 2025 | Feb 19, 2025 | Certified |
| Computational Biologist - Senior Scientist I | $101,611 Level I | Cambridge, MA | Dec 3, 2024 | Dec 3, 2024 | Certified |
| Executive Director of Technical Operations | $260,000 Level III | Cambridge, MA | Sep 13, 2024 | Oct 18, 2024 | Certified, then withdrawn |
| Associate Scientist | $105,000 Level I | Cambridge, MA | May 8, 2024 | Oct 1, 2024 | Certified, then withdrawn |
| Chief Therapeutics Officer | $385,700 Level IV | Cambridge, MA | Sep 29, 2023 | Oct 27, 2023 | Certified, then withdrawn |
| Scientist II, In Vivo Research and Development | $125,000 Level III | Cambridge, MA | Sep 13, 2023 | Sep 25, 2023 | Certified |
| Medical Director | $220,000 Level IV | Cambridge, MA | Sep 11, 2023 | Oct 1, 2023 | Certified, then withdrawn |
| Senior Stem Cell Scientist | $124,000 Level IV | Cambridge, MA | May 6, 2022 | Oct 1, 2022 | Certified, then withdrawn |
| Vice President of Research and Development | $285,848 Level III | Natick, MA | Oct 4, 2021 | Oct 10, 2021 | Certified, then withdrawn |
Salaries are the lower end of the wage offered on each application, converted to a yearly amount; statistics use certified full-time applications only. An LCA is not a visa approval and one LCA can cover several positions. Source: U.S. Department of Labor, OFLC LCA Disclosure Data, fiscal years 2023–2026 (latest decision Jun 30, 2026).